echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > CA (IF=509) System introduction of radiotherapy and improved technology in clinical application (worthy of collection)

    CA (IF=509) System introduction of radiotherapy and improved technology in clinical application (worthy of collection)

    • Last Update: 2021-12-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Editor's note The iNature public account is jointly created by a team of doctors from Tsinghua University, Harvard University, Chinese Academy of Sciences and other institutions.
    The iNature talent public account is now launched, focusing on talent recruitment, academic progress, and scientific research information.
    If you are interested, you can long press or scan below Follow us on the QR code
    .

    iNature radiotherapy (RT) is the recognized cornerstone of tumor treatment
    .

    It is estimated that 40% to 60% of cancer patients will benefit from radiotherapy at some stage in the treatment process
    .

    Adaptive radiotherapy (ART) is a new method through which radiotherapy can be developed
    .

    Using the ART method, computed tomography or magnetic resonance (MR) images are obtained as part of the treatment delivery process
    .

    This enables the irradiation volume to adapt to changes in the position, movement, size or shape of the organ and/or tumor that may occur during the treatment
    .

    For oncologists and clinicians outside of radiation oncology, the advantages and challenges of ART may be somewhat abstract
    .

    ART is targeted to affect many different types of cancer
    .

    The use and application of this new technology should be understood by the entire oncology community so that it can be properly integrated in the field of cancer treatment
    .

    Likewise, there is an urgent need to test these advances
    .

    MR-guided ART (MRgART) is a new and extended ART mode, which expands and further improves the functions of ART
    .

    MRgART provides a unique opportunity to iteratively improve adaptive image guidance
    .

    However, although the MRgART adaptive process advances ART to levels not reached before, it can be more expensive, time-consuming, and complicated
    .

    On November 18, 2021, the William A.
    Hall team from the Medical College of Wisconsin published an online review titled "Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians" in CA: A Cancer Journal for Clinicians (IF=509) The article, this review provides clinicians with an overview, describing the process of ART, especially MRgART
    .

    This review focuses on the concept of adaptive RT (ART), more specifically, magnetic resonance (MR) guided ART (MRgART), which is achieved by integrating MR imaging (MRI) scanners into linear accelerators (linacs) Realized used to transmit radiation
    .

    The purpose of this review is to show how this new type of RT differs from historical RT, and how it can be positioned to potentially improve RT-related results
    .

    Radiotherapy (RT) is the recognized cornerstone of cancer treatment
    .

    It is estimated that 40% to 60% of cancer patients will benefit from radiotherapy at some stage in the treatment process
    .

    It is estimated that 1.
    8 million new cancer cases occurred in the United States in 2020 alone
    .

     This means that among these patients, approximately 900,000 patients may require radiotherapy
    .

    The significant impact of this number makes radiotherapy one of the most common single tumor treatment options for cancer patients
    .

    Therefore, meaningful improvements in RT will affect hundreds of thousands of cancer patients every year
    .

    Researching the best use of radiotherapy is an extremely important part of understanding the overall progress of cancer treatment
    .

    Like many cancer therapies, RT is developing rapidly
    .

    The improvement of RT is the result of a number of technological advancements
    .

    With the advancement of computing and imaging, each item will have an important impact on the method of radiotherapy
    .

    These technological advancements attempt to overcome the major limitations of RT
    .

    Well-designed, prospective, multi-institutional clinical trials are needed to determine whether the proposed progress provides clinical benefit, and methods to improve RT need to be continuously introduced and evaluated
    .

    Radiation oncologists, medical oncologists, radiologists, clinical trialists, and patient advocates need to understand these advancements in order to test them in a robust manner
    .

    This review focuses on the concept of adaptive RT (ART), more specifically, magnetic resonance (MR) guided ART (MRgART), which is achieved by integrating MR imaging (MRI) scanners into linear accelerators (linacs) Realized used to transmit radiation
    .

    The purpose of this review is to show how this new type of RT differs from historical RT, and how it can be positioned to potentially improve RT-related results
    .

    The use of radiotherapy for many solid tumors is still an important part of organ-sparing and/or multimodal cancer treatment
    .

    In fact, image guidance has increased the indications of RT in various situations
    .

    The role of ART, especially MRgART, is constantly evolving
    .

    Here, the review outlines many different clinical situations in which ART, and more specifically MRgART, may have clinical advantages
    .

    These advantages will include the potential to reduce acute and late toxicity, improve local control, and ideally improve the OS of certain malignancies
    .

    Recognizing biological rather than rigorous anatomical targets represents an exciting aspect of MR-based ART, which may have a wide range of impacts, including a shift from the current use of historical radiation doses based on tumor histology and tumor staging, and May cause imaging response-mediated dose
    .

    However, oncologists must recognize that prospective random data is needed to evaluate these types of new treatment strategies
    .

    In the future, radiation oncologists may receive a large amount of additional data, including bioimaging data, daily adaptation data, and real-time treatment information
    .

    The meaning of these data must be collected, analyzed and understood
    .

    The benefits to patients must be quantified and tested vigorously
    .

    Whether this method can ultimately improve the clinical outcomes of patients with various malignancies requires a lot of prospective evaluation
    .

    Reference message: https://acsjournals.
    onlinelibrary.
    wiley.
    com/doi/full/10.
    3322/caac.
    21707
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.